Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded

Nature Reviews Microbiology

Volumn 6, Issue 7, 2008, Pages 529-540

  Cattaneo, Roberto ^a   Miest, Tanner ^a   Shashkova, Elena V ^a   Barry, Michael A ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE; FLUOROURACIL; H 101; MACROGOL; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC MEASLES VIRUS; ONCOLYTIC MYXOMA VIRUS; ONCOLYTIC REOVIRUS; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; ONYX 015; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; PROTEINASE; PV 701; RAPAMYCIN; VIROTHERAPY AGENT;

ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE DEFICIENCY; LEUKEMIA; MYELOMA; NASOPHARYNX CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SQUAMOUS CELL CARCINOMA; TRANSGENE; VIRAL GENETICS; VIROGENESIS; VIROTHERAPY; VIRUS CAPSID; VIRUS ENVELOPE; VIRUS REPLICATION;

DRUG DELIVERY SYSTEMS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUSES;

MIRIDAE;

EID: 45449114994     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro1927     Document Type: Review

References (117)

1. Dock, G. The influence of complicating diseases upon leukemia. Am. J. Med. Sci. 127, 563-592 (1904).
2. Sinkovics. J. & Horvath, J. New developments in the virus therapy of cancer: A historical review. Intervirology 36, 193-214 (1993).
3. Kelly, E. & Russell, S. J. History of oncolytic viruses: Genesis to genetic engineering. Mol. Ther. 15, 651-659 (2007).
4. Hoster, H., Zanes, R. & Vonhaam, E. The association of "viral" hepatitis and Hodgkin's disease. Cancer Res. 9, 473-480 (1949).
5. Moore, A. E. Viruses with oncolytic properties and their adaptation to tumors. Ann NY Acad. Sci. 54, 945-952 (1952).
6. Southam, C. M. & Moore, A. E. Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer 5, 1025-1034 (1952).
7. Newman, W. & Southam, C. M. Virus treatment in advanced cancer: A pathological study of fifty-seven cases. Cancer 7, 106-118 (1953).
8. Huebner, R. J., Rowe, W. P., Schatten, W. E., Smith, R. R. & Thomas, L. B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9, 1211-1218 (1956).
9. Suskind, R. G., Fuebner, R. J., Rowe, W. P. & Love, R. Viral agents oncolytic for human tumors in heterologous host; oncolytic effect of Coxsackie B viruses. Proc. Soc. Exp. Biol. Med. 94, 309-318 (1957).
10. Pond, A. R. & Manuelidis, E. E. Oncolytic effect of poliomyelitis virus on human epidermoid carcinoma (hela tumor) heterologously transplanted to guinea pigs. Am. J. Pathol. 45, 233-249 (1964).
11. Hammon, W. M., Yohn, D. S., Casto, B. C. & Atchison, R. W. Oncolytic potentials of nonhuman viruses for human cancer. J Natl Cancer Inst. 31, 329-345 (1963).
12. Molomut, N. & Padnos, M. Inhibition of transplantable and spontaneous murine tumours by the M-P virus. Nature 208, 948-950 (1965).
13. Yohn, D. S., Hammon, W. M., Atchison, R. W. & Casto, B. C. Oncolytic potentials of nonhuman viruses for human cancer. II. Effects of five viruses on heterotransplantable human tumors. J Natl Cancer Inst. 41, 523-529 (1968).
14. Shashkova, E. V., Spencer, J. F., Wold, W. S. & Doronin, K. Targeting interferon-α increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol. Ther. 15 598-607 (2007).
15. Doyle, T. C., Burns, S. M. & Contag, C. H. In vivo bioluminescence imaging for integrated studies of infection. Cell. Microbiol. 6 303-317 (2004).
16. Piwnica-Worms, D., Schuster, D. P. & Garbow, J. R. Molecular imaging of host-pathogen interactions in intact small animals. Cell. Microbiol. 6, 319-331 (2004).
17. Peng, K. W. et al. Pharmacokinetics of oncolytic measles virotherapy: Eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther. 13, 732-738 (2006).
18. Liu, T. C., Galans, E. & Kim, D. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nature Clin. Pract. Oncol. 4, 101-117 (2007).
19. Klenk, H. D. & Garten, W. Host cell proteases controlling virus pathogenicity. Trends Microbiol. 2, 39-43 (1994).
20. Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 161- 174 (2002).
21. Morling, F. J., Peng, K. W., Cosset, F. L. & Russell, S. J. Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. Virology 234, 51-61 (1997).
22. Peng, K. W., Vile, R., Cosset, F. L. & Russell, S. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther. 6, 1552-1557 (1999).
23. Kinoh, H. et al. Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases. Gene Ther. 11, 1137-1145 (2004).
24. Springfeld, C. et al. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res. 66, 7694-7700 (2006).
25. Andreasaen, P. A., Egelund, R. & Petersen, H. H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 57, 25-40 (2000).
26. Waehler, R., Russell, S. J. & Curiel, D. T. Engineering targeted viral vectors for gene therapy. Nature Rev. Genet. 8, 573-587 (2007).
27. Campos, S. K. & Barry, M. A. Current advances and future challenges in adenoviral vector biology and targeting. Curr. Gene Ther. 7, 189-204 (2007).
28. Navaratnarajah, C. K., Leonard, V. H. L. & Cattaneo, R. in Measles Virus (Springer, Heidelberg, in the press).
29. Lamb, R. A., Paterson, R. G. & Jardetzky, T. S. Paramyxovirus membrane fusion: Lessons from the F and HN atomic structures. Virology 344, 30-37 (2006).
30. Tatsuo, H., Ono, N., Tanaka, K. & Yanagi, Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 406, 893-897 (2000).
31. Dorig, R. E., Marcil, A., Chopra, A. & Richardson, C. D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75, 295-305 (1993).
32. Naniche, D. et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 67, 6025-6032 (1993).
33. Vongpunsawad, S., Oezgun, N., Braun, W. & Cattaneo, R. Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM-or CD46-induced fusion and their localization on a new hemagglutinin structural model. J. Virol. 78, 302-313 (2004).
34. Schneider, U., Bullough, F, Vongpunsawad, S., Russell, S. J. & Cattaneo, R. Recombinant measles viruses efficiently entering cells through targeted receptors. J. Virol. 74, 9928-9936 (2000).
35. Hammond, A. L. et al. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J. Virol. 75, 2087-2096 (2001).
36. Bucheit, A. D. et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol. Ther. 7, 62-72 (2003).
37. Peng, K.-W. et al. Oncolytic measles virus displaying a single chain antibody against CD38, a myeloma cell marker. Blood 101 2557-2562 (2003).
38. Ungerechts, G. et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol. Ther. 15, 1991-1997 (2007).
39. Nakamura, T. et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nature Biotechnol. 23, 209-214 (2005).
40. Zhou, G. & Roizman, B. Construction and properties of a herpes simplex virus I designed to enter cells solely via the IL- 13α2 receptor. Proc. Natl Acad. Sci. USA 103, 5508-5513 (2006).
41. Hedley, S. J. et al. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther. 13, 88-94 (2006).
42. Belousova, N. et al. Genetically targeted adenovirus vector directed to CD40-expressing cells. J. Virol. 77, 11367-11377 (2003).
43. Berk, A. J. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24, 7673-7685 (2005).
44. Kim, J., Kim, J. H., Choi, K. J., Kim, P, H. & Yun, C. O. E1A-and E1B-double mutant replicating aclenovirus elicits enhanced oncolytic and antitumor effects. Hum. Gene Ther. 18, 773-786 (2007).
45. Kim, E. et al. Ad-mTERT-A19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum. Gene Ther. 14, 1415-1428 (2003).
46. Kuppuswamy, M. et al. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther. 12, 1607-1617 (2005).
47. Barker, D. D. & Berk, A. J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107-121 (1987).
48. Bischoff, J. R. et al. An adenovirus mutant that replicates selectively in p53-deficent hurnan tumor cells. Science 274, 373-376 (1996).
49. Goodrum, F. D. & Ornelies, D. A. p53 status does not determine outcome of E1B 55-kilodalton, mutant adenovirus lytic infection. J. Virol. 72, 9479-9490 (1998).
50. O'Shea, C. C., Soria, C., Bagus, B. & McCormick, F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 8 61-74 (2005).
51. O'Shea. C. C. et al. Late viral RNA export, rather than P53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6, 611-623 (2004).
52. Chung, R. Y., Saeki, Y. & Chiocca, E. A, B-mgb promoter, retargeting of herpes simplex virus γ34.5 gene mediated virulence toward tumor and cycling cells. J. Virol. 73, 7556-7564 (1999).
53. Markert, J. M. et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther. 7, 867-874 (2000).
54. Kanai, R. et al. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi 1 promoter retargeting of γ34.5-mediated virulence. Gene Ther. 13, 106-116 (2006).
55. Kambara, H., Okano, H., Chiocca, E. A. & Saeki, Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 65, 2832-2839 (2005).
56. Randall, R. E. & Goodbourn, S. Interferons and viruses: An interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89, 1-47 (2008).
57. Linge, C., Gewert, D., Rossmann, C., Bishop, J. A. & Crowe, J. S. lnterferon system defects in human malignant melanoma. Cancer Res. 55, 4099-4104 (1995).
58. Matin, S. F. et al. Impaired α-interferon signaling in transitional cell carcinoma: Lack of p48 expression in 5637 cells. Cancer Res. 61, 2261-2266 (2001).
59. Ralph, S. J. et al. Resistance of melanoma cell lines to interferons correlates with reduction of IFN-induced tyrosine phosphorylation. Induction of the anti-viral state by IFN is prevented by tyrosine kinase inhibitors. J. Immunol. 154, 2248-2256 (1995).
60. Sun, W. H. et al. Interferon-α resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 91, 570-576 (1998).
61. Wong, L. H. et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3γ. J. Biol. Chem. 272, 28779-28785 (1997).
62. Stojdl, D. F. et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4, 263-275 (2003).
63. Aaronson, D. S. & Horvath, C. M. A road map for those who don't know JAK-STAT. Science 296, 1653-1655 (2002).
64. Darnell, J. E. J. STATS and gene regulation. Science 277, 1630-1635 (1997).
65. Samuel, C. E. Antiviral actions of interferons. Clin. Microbiol. Rev. 14, 778-809 (2001).
66. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H. & Schreiber, R. D. How cells respond to interferons Annu. Rev. Biochem. 67, 227-264 (1998).
67. Conzelmann, K. K. Transcriptional activation of α/β interferon genes: interference by nonsegmented negative-strand RNA viruses. J. Virol. 79, 5241-5248 (2005).
68. Garcia-Sastre, A. Mechanisms of inhibition of the host interferon α-β-mediated antiviral responses by viruses. Microbes Infect. 4, 647-655 (2002).
69. Takeuchi, K., Kadota, S. I., Takeda, M., Miyajima, N. & Nagata, K. Measles virus V protein blocks interferon (IFN)-α/β but not IFN-γ signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Lett. 545, 177-182 (2003).
70. Horvath, C. M. Weapons of STAT destruction. Interferon evasion by paramyxovirus V protein. Eur. J. Biochem. 271, 4621-4628 (2004).
71. Palosaari, H., Parisien, J. P., Rodriguez, J. J., Ulane, C. M. & Horvath, C. M. STAT protein interference and suppression of cytokine signal transduction by measles virus V protein. J. Virol. 77 7635-7644 (2003).
72. Devaux, P., von Messling, V., Songsungthong, W., Springfield, C. & Cattaneo, R. Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology 360, 72-83 (2007).
73. Haralambieva, I. et al. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol. Ther. 15, 588-597 (2007).
74. Ohno, S., Ono, N., Takeda, M., Takeuchi, K. & Yanagi, Y. Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction. J. Gen. Virol. 85, 2991-2999 (2004).
75. Childs, K. et al. mda-5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology 359, 190-200 (2007).
76. Doronin, K. et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74, 6147-6155 (2000).
77. Fueyo, J. et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12 (2000).
78. Boviatsis, E. J. et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 54 5745-5751 (1994).
79. Chase, M., Chung, R. Y. & Chiocca, E. A. An oncolytic viral rrutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nature Biotechnol. 16, 444-448 (1998).
80. Searle, P. F. et al. Nitroreductase: A prodrug-activating enzyme for cancer gene therapy. Clin. Exp. Pharmacol. Physiol. 31, 811-816 (2004).
81. Freytag, S. O., Rogulski, K. R., Paielli, D. L., Gilbert, J. D. & Kim, J. H. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9, 1323-1333 (1998).
82. Mi, J., Li, Z., Ni, S., Steinwaerder, D. & Lieber, A. Induced apoptosis supports spread of adenovirus vectors in tumors. Hum. Gene Ther. 12, 1343-1352 (2001).
83. Sova, P. et al. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol. Ther. 9, 496-509 (2004).
84. Dong, F. et al. Eliminating established tumor in nu/nu nude mice by a TRAIL-armed oncolytic adenovirus. Clin. Cancer Res. 12, 5224-5230 (2006).
85. Ren, X.-W. et al. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. Cancer Gene Ther. 13, 159-168 (2006).
86. Sauthoff, H. et al. Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2- and E1b-55kD-mediated degradation of p53. Cancer Gene Ther. 13, 686-695 (2006).
87. Idema, S. et al. AdΔ24 and the p53-expressing variant AdΔ24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy. J. Gene Med. 9, 1046-1056 (2007).
88. Zhang, J. F. et al. Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc. Natl Acad. Sci. USA 93, 4513-4518 (1996).
89. Vile, R., Ando, D. & Kirn, D. The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider. Cancer Gene Ther. 9, 1062-1067 (2002).
90. Peng, K. W. et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98, 2002-2007 (2001).
91. Ikeda, K, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nature Med. 5, 881-887 (1999).
92. Lamfers, M. L. et al. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol. Ther. 14, ? (2006).
93. Stanford, M. M., Barrett, J. W., Nazarian, S. P., Werden, S. & McFadden, G. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells J. Virol. 81, 1251-1260 (2007).
94. Lun, X. O. et al. Targeting human medulloblastoma: Oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res. 67, 8818-8827 (2007).
95. Yamauchi, K. et al. Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: An opposite effect of chemotherapy. Cancer Res. 68, 516-520 (2008).
96. Parks, R., Evelegh, C. & Graham, F. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther. 6, 1565-1573 (1999).
97. Morral, N. et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl Acad. Sci. USA 96, 12816-12821 (1999).
98. Hemminki, A. et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol. Ther. 7, 163-173 (2003).
99. Xiang, Z. O. et al. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J. Virol. 77, 10780-10789 (2003).
100. Rose, N. F. et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 539-549 (2001).
101. von Mossling, V., Zimmer, G., Herrler, G., Haas, ? & Cattaneo, R. The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity. J. Virol. 75, 6418-6427 (2001).
102. Croyle, M. A., Chirmule, N., Zhang, Y. A. & Wilson, J. M. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75, 4792-4801 (2001).
103. Fisher, K. D. et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralizing antibodies. Gene Ther. 8 341-348 (2001).
104. Hofherr, S. E., Mok, H., Gushiken, F. C., Lopez, ? A. & Barry, M. A. Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum. Gene Ther. 18, 837-848 (2007).
105. Lanciotti, J. et al. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol. Ther. 8, 99-107 (2003).
106. Mok, H., Palmer, D. J., Ng, P. & Barry, M. A. Evaluation of polyethylene glycol modification of first generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 11, 66-79 (2005).
107. O'Riordan, C. R. et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 10, 1349-1358 (1999).
108. Fisher, K. D. et al. Passive tumor targeting of polymer-coated adenovirus for cancer gene therapy. J. Drug Target. 15, 546-551 (2007).
109. Harrington, K. & Vile, R. Virus smuggling, tax evasion and tumor assassination. Nature Med. 12, 507-509 (2006).
110. Munguia, A., Ota, T., Miest, T. & Russell, S. J. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther. 15, 797-806 (2008).
111. Khuri, F. R. et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Med. 6, 879-885 (2000)
112. Freytag, S. O. et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal readiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 63, 7497-7506 (2003).
113. Barton, K. N. et al. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol. Ther. 13, 347-356 (2006).
114. Ungerechts, G. et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res. 67, 10939-10947 (2007).
115. Jackson, R. J. et al. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75, 1205-1210 (2001).
116. Shashkova, E. V., Kuppuswarmy, M. N., Wold, W. S. & Doronin, K. Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther. 15, 61-72 (2008).
117. Hashiguchi, T. et al. Crystal structure of measles virus hemagglutinin provides insight into effective vaccines. Proc. Natl Acad. Sci. USA 104, 19535-19540 (2007).